drugset / Trial / NCT02315495
Combining Saxagliptin and Acarbose to Improve Postprandial Glycaemia in Type 2 Diabetes
RandomizedCrossoverOpen-labelTreatment
Summary
The proposed study is designed to evaluate (i) the effects of saxagliptin, with or without acarbose, on gastric emptying, postprandial glycaemia, and plasma intact GLP-1, insulin, C-peptide and glucagon after a high carbohydrate meal, and (ii) whether the magnitude of the effects of saxagliptin and/or acarbose is related to the rate of gastric emptying, in patients with type 2 diabetes.
Timeline
- Start
- 2015-04-03
- Primary completion
- 2016-08-26
- Completion
- 2016-08-26
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Acarbose | Unknown | 100 mg | — |
| Subject | SAXAGLIPTIN ANHYDROUS | Small molecule | 5 mg | — |